Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma.
暂无分享,去创建一个
Shing M. Lee | G. Schwartz | I. Chen | M. Ingham | E. Choy | Lauren Taiclet | Shahnaz V. Singh-Kandah | Parag P. Patwardhan